This retrospective study explored the response to treatment and prognosis of patients with KRAS-mutant NSCLC who received ICIs with or without combination chemotherapy as first- or second-line treatments compared with chemotherapy alone, compared with published clinical studies of NSCLC patients who received ICIs. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.